Apyx Medical (APYX) Cash from Operations (2011 - 2026)

Apyx Medical (APYX) has reported Cash from Operations for 16 consecutive years, with -$3.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Operations fell 183.05% year-over-year to -$3.5 million; the trailing twelve-month figure through Jun 2026 stood at -$10.1 million (down 8.76% YoY), and the FY2025 full-year result was -$8.0 million, up 55.67% from the prior year.
• Cash from Operations declined to -$3.5 million in Q2 2026 per APYX's latest filing, from -$572000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at $3.7 million in Q3 2023 and bottomed at -$6.3 million in Q1 2024.
• Historically, Cash from Operations has averaged -$3.1 million across 5 years, with a median of -$3.5 million in 2025.
• The sharpest annual moves came in 2022 and 2023: Cash from Operations sank 2216.82% in 2022, then surged 168.96% in 2023.
• Over 5 years, Cash from Operations stood at -$4.5 million in 2022, then soared by 51.17% to -$2.2 million in 2023, then plunged by 32.78% to -$2.9 million in 2024, then climbed by 13.86% to -$2.5 million in 2025, then slumped by 37.94% to -$3.5 million in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered -$3.5 million, -$572000.0, and -$2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.